Biotechnology

LadRx Corporation

LadRx Plans to Seek FDA Approval for Aldoxorubicin

LadRx Corporation released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0, actual EPS USD -1.4528

LadRx Corporation released FY2024 Q4 earnings on March 28, 2025 (EST), with actual revenue of 0 USD and EPS of 0.6687 USD

LadRx Corporation released FY2024 annual earnings on March 28, 2025 (EST), with actual revenue of 0 USD and EPS of -3.2108 USD

LadRx Corporation released FY2024 Cumulative 3Q earnings on November 14 (EST), with actual revenue of 0 and EPS of -3.8796

LadRx Corporation released FY2024 Q3 earnings on November 14 (EST), with actual revenue of 0 USD and EPS of -1.6654 USD

LadRx Corporation released FY2023 Q4 earnings on March 27 (EST) with actual revenue of 0 USD and EPS of -1.7324 USD

LadRx Corporation released FY2023 Cumulative 3Q Earnings on November 14, 2023 (EST), with Revenue 0 and EPS 2.3181

SMX Security Matters

Regencell Bioscience

Nuvve

Bristol-Myers Squibb Company

Innovative Eyewear

Monte Rosa Therapeutics

PELICAN ACQUISITION CORPORATION SHS USD0.0001(S/R 02/05/2030)

Century Therapeutics

Novabay Pharmac

Erasca

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

LadRx Corporation(LADX.US)